Every 10-Q that Regeneron Pharmaceuticals Inc (REGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow REGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REGN filings page.
Regeneron Pharmaceuticals reported Q3 2025 results. Revenue was $3,754.3 million, slightly above last year’s $3,720.7 million. Net income rose to $1,460.0 million with diluted EPS of $13.62, up from $11.54.
Product sales softened while collaboration income grew. Net product sales were $1,587.7 million versus $1,946.4 million, reflecting lower U.S. EYLEA family sales ($1,111.2 million vs $1,536.9 million) and higher global Libtayo sales ($365.2 million vs $288.6 million). Collaboration revenue increased to $1,968.4 million from $1,660.1 million, including contributions from Sanofi and Bayer.
Year-to-date operating cash flow reached $3,808.2 million. The company repurchased 1.1 million shares in Q3 for $663.0 million (4.5 million shares for $2,785.3 million year-to-date) and declared a $0.88 quarterly dividend in October. Total assets were $40,169.4 million and stockholders’ equity was $30,957.8 million as of September 30, 2025.